To investigate the efficacy of intravitreal ranibizumab injections in proliferative diabetic retinopathy associated with vitreous hemorrhage (VH).
A prospective study including patients with proliferative diabetic retinopathy who presented with persistent VH. Vitreous hemorrhage was graded into mild, moderate, and severe. Patients were randomized into two groups: the ranibizumab group was treated with intravitreal injections of ranibizumab and the control group was assigned to observation alone. Vitrectomy was performed if there was any aggravation of the VH in patients with mild, moderate, and severe VH or in the absence of improvement by 16 weeks in patients with moderate and severe VH.
The ranibizumab group included 71 patients and the control group included 62 patients. There was a statistically significant difference in the vitrectomy rate in patients with mild-to-moderate VH (5 patients [7.04%] and 12 patients [19.35%], respectively; P = 0.04). However, there was no statistically significant difference in the overall vitrectomy rate, and in the vitrectomy rate in severe VH (17 [23.94%] and 12 [16.90%] patients in the ranibizumab group vs. 22 [35.48%] and 10 [16.13%] patients in the control group, P = 0.14 and P = 0.83, respectively). Recurrence of the VH occurred in 22 patients in the ranibizumab group and 29 patients in the control group (P = 0.06). Better visual acuity measurements were recorded on all follow-up visits in the ranibizumab group (P ≤ 0.04).
Intravitreal ranibizumab injections could be considered in proliferative diabetic retinopathy patients with mild and moderate VH.
Intravitreal ranibizumab injections could be considered in proliferative diabetic retinopathy associated with mild and moderate vitreous hemorrhage.
*Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon;
†Eye and Ear University Hospital, Ophthalmology Department, Naccash, Lebanon; and
‡Faculty of Medicine, Saint-Esprit University, Kaslik, Lebanon.
Reprint requests: Joseph B. Nehme, MD, 170 Boulevard du Montparnasse, Paris, France 75014; e-mail: email@example.com
None of the authors has any financial/conflicting interests to disclose.